AnaptysBio, Inc.
9
0
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.1%
1 terminated/withdrawn out of 9 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
Role: lead
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
Role: lead
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
Role: lead
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
Role: lead
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
Role: lead
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Role: lead
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
Role: lead
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Role: lead
Analysis of Peripheral Blood ILC2s and Th2 Cells in Response to ANB020
Role: collaborator
All 9 trials loaded